{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T11:13:06Z","timestamp":1737112386548,"version":"3.33.0"},"reference-count":25,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CCID"],"DOI":"10.2147\/ccid.s490820","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:45:14Z","timestamp":1737110714000},"page":"151-159","source":"Crossref","is-referenced-by-count":0,"title":["Dermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-6365","authenticated-orcid":true,"given":"Laila","family":"Tsaqilah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ananda","family":"Putri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3359-6950","authenticated-orcid":true,"given":"Erda","family":"Avriyanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5582\/bst.2018.01246","volume":"12","author":"Peng","year":"2018","journal-title":"BioSci Trends"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e763","DOI":"10.7759\/cureus.763","volume":"8","author":"Osborn","year":"2016","journal-title":"Cureus"},{"key":"ref3","unstructured":"Cancer Care Alberta Guideline Resource Unit. Prevention and Treatment of Acneiform Rash in Patients Treated with EGFR Inhibitor Therapy. Accessed September 19, 2023. Available from: https:\/\/www.albertahealthservices.ca\/assets\/info\/hp\/cancer\/if-hp-cancer-guide-supp003-egfri-rash.pdf."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1007\/s00520-016-3231-1","volume":"24","author":"Braden","year":"2016","journal-title":"Support Care Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1010052","DOI":"10.3389\/fonc.2022.1010052","volume":"12","author":"Yang","year":"2023","journal-title":"Front Oncol"},{"key":"ref6","volume-title":"Profile of Dermatologic Side Effects of Tyrosine Kinase Inhibitor (EGFR-Tkis) in Lung Cancer Patients","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"103305","DOI":"10.1016\/j.critrevonc.2021.103305","volume":"160","author":"Zhao","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1586\/era.13.30","volume":"13","author":"Lacouture","year":"2013","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.jfma.2017.03.001","volume":"116","author":"Chu","year":"2017","journal-title":"J Formos Med Assoc"},{"key":"ref11","volume":"21","author":"Lu","year":"2024","journal-title":"J Formos Med Assoc"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3889\/oamjms.2019.170","volume":"7","author":"Annunziata","year":"2019","journal-title":"Open Access Maced J Med Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"Park","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.lungcan.2018.10.028","volume":"127","author":"Halmos","year":"2019","journal-title":"Lung Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.21037\/jtd-23-686","volume":"15","author":"Gilardone","year":"2023","journal-title":"J Thorac Dis"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1283807","DOI":"10.3389\/fmed.2023.1283807","volume":"10","author":"Dan","year":"2024","journal-title":"Front Med"},{"key":"ref18","first-page":"9136249","volume":"31","author":"Fuggetta","year":"2019","journal-title":"Scientifica"},{"key":"ref19","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017. Accessed September 19, 2023. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00204-014-1244-4","volume":"88","author":"Pastore","year":"2014","journal-title":"Arch Toxicol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"192","DOI":"10.4103\/0378-6323.168914","volume":"82","author":"Miguel-Gomez","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.jaad.2020.03.055","volume":"85","author":"Kremer","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1365-2230.2008.02882.x","volume":"33","author":"Ena","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/ijt.ijt_16_16","volume":"8","author":"Pirmez","year":"2016","journal-title":"Int J Trichol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000475543","volume":"8562","author":"Fukui","year":"2017","journal-title":"Case Rep Dermatol"}],"container-title":["Clinical, Cosmetic and Investigational Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/99345","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/99345","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:45:18Z","timestamp":1737110718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/dermatologic-adverse-events-following-afatinib-in-a-woman-with-non-sma-peer-reviewed-fulltext-article-CCID"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":25,"URL":"https:\/\/doi.org\/10.2147\/ccid.s490820","relation":{},"ISSN":["1178-7015"],"issn-type":[{"value":"1178-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}